Publications

Published Works

IP in the digital age: a tricky path ahead for pharma companies?

The pharmaceutical industry is becoming increasingly interested in digital health, and serious money is being invested in the technology.

Hogan Lovells Publications

The market for biosimilars is growing in spite of unanswered questions

A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and...

Published Works

Shifting Attitudes to Injunctions in Patent Cases

Until relatively recently, the question of whether a final injunction should be granted to a patentee who has succeeded at trial has not really troubled the courts of Europe. Although the...

Hogan Lovells Publications

Focus on Life Sciences Industry Trends for 2013

Dear Clients and Friends,

Hogan Lovells Publications

CJEU rules on negative term and zero term SPCs: The Januvia case decision

The Court of Justice of the European Union (CJEU) gave its decision in the Januvia case today, 8 December 2011. The decision has implications not only for the parties involved, but also for ...

Hogan Lovells Publications

CJEU rules on combination SPCs: The Medeva case decision

The Court of Justice of the European Union (CJEU) gave its opinion on the Medeva and Georgetown cases today, 24 November 2011. The decisions have implications not only for the parties...

Hogan Lovells Publications

Ban on embryonic stem cell patenting in Europe

The Court of Justice of the European Union (CJ-EU) has handed down its long-awaited judgment in the Brüstle case on the patentability of stem cell inventions.  Read article.

;
Loading data